News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Health Plans Stumble on AI Without Fixing Data First
Payers are investing in AI tools but lack the foundational data governance needed to deploy them. A July 22 webinar explores why identity resolution and data quality matter more than model selection.
Biotech IPO window opening later in 2025, but only for proven companies
Investors and bankers at BIO 2026 predict a pickup in biotech offerings this year — but limited to firms meeting stricter criteria. What changed since the 2024 drought.
HHS fast-tracks U.S. drug trials to counter China's research advantage
U.S. Department of Health and Human Services is reforming early-stage clinical trial rules to pull biotech companies away from overseas testing. New policies aim to make domestic trials faster and more competitive.
Kardigan IPO hits $400M after MyoKardia acquisition windfall
Kardigan brought late-stage biotech assets and MyoKardia's team to market in a $400M IPO. CEO Tassos Gianakakos credits the portfolio depth and talent influx as investor draws, alongside the SpaceX timing tailwind.
Pfizer's Seagen lung cancer drug flops in trial
Sigvotatug vedotin, acquired as part of Pfizer's $43 billion Seagen purchase, failed to meet endpoints in a lung cancer study. Analysts remain divided on the drug's prospects in ongoing trials.
Ollin raises $330M to test AMD drug challenger after head-to-head win
Ollin Biosciences secured $330M in funding after its licensed drug showed advantages over Roche's Vabysmo in a comparative trial. The capital will fund pivotal tests ahead of potential regulatory submission.
Insulet hires first chief R&D officer as pump makers clash
Insulet appointed Divakar Ramakrishnan, who previously led R&D at Convatec and Eli Lilly, as its inaugural chief R&D officer. The move signals the insulin-pump maker is doubling down on innovation amid intensifying competition.
Medtronic names J&J finance veteran as first CFO of innovation
Eric Lenard, with 20+ years in medtech finance, takes new role as Medtronic signals deeper commitment to R&D spending and organizational restructuring around innovation.
Hackensack Meridian and Hunterdon Health explore merger in New Jersey
Two financially stable New Jersey hospital systems are exploring a merger to increase competitive leverage against larger regional rivals. Both operate independently today.
HHS fast-tracks early drug trials in U.S. to compete with China
The Department of Health and Human Services is streamlining clinical trial rules to keep pharmaceutical companies from running early research overseas. What changes and who benefits.
HCA's chief clinical officer exits after 4 years in role
Dr. Michael Cuffe, who led clinical strategy at HCA Healthcare since 2022, is departing at end of August. The exit signals potential shifts in the health system's AI and clinical operations agenda.
MultiCare names successor as CEO Robertson retires end of 2026
William Robertson, CEO of the Washington-based nonprofit health system, will step down Jan. 1, 2027. Florence Chang, a longtime executive, will take the helm. What this means for strategy and operations.